Introduction: Psoriasis is a chronic disease accompanied by angiogenesis and inflammation, significantly affecting patients' quality of life. Its pathophysiology has not been fully elucidated. Endocan, VEGF, CXCL12, and NGF are molecules involved in inflammation and angiogenesis. There is a restricted size of studies investigating the relationship of these molecules with psoriasis. The study aims to determine the levels of endocan, VGEF, CXCL12, and NGF in psoriasis patients, identify the relationship of these parameters with illness intensity and define the correlation between serum endocan level and VGEF, CXCL12, and NGF.
Materials and Methods: In this study, endocan, VGEF, CXCL12, and NGF levels were determined in the serum of 100 healthy persons and 94 psoriasis patients using the ELISA method and compared with the control group. Illness violence was grouped with the Psoriasis Area and Severity Index (PASI); Endocan, VGEF, CXCL12, and NGF levels were compared according to disease severity. Correlation analysis was performed between endocan and VGEF, CXCL12, and NGF in psoriasis.
Results: Endocan, VGEF, CXCL12, and NGF levels were high in psoriasis. It was determined that as the severity of the disease increased, the serum levels of these parameters increased. A moderate positive correlation was found between Endocan and CXCL12 and NGF.
Conclusion: Serum Endocan and NGF levels increase with disease severity; Endocan and NGF can be used as target molecules in psoriasis treatment.
Key words: Psoriasis; Endocan; VEGF; CXCL12; NGF; Psoriasis Area and Severity Index
|
